OPSYNVI® (macitentan and tadalafil)
- Disease State Information & Resources
- Guidelines
- Pivotal Clinical Trial Publications
- Search Medical Information
- U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)